New research published in JAMA Oncology reports how two separate DNA changes appear to predict aggressive childhood leukaemias when they occur in combination.
Over the course of a decade of work in several study sites spanning multiple continents, the researchers evaluated tumour characteristics of more than 1,300 childhood cancer patients who were diagnosed with B-cell acute lymphoblastic leukaemia (ALL), a type of cancer that affects the white blood cells of the bone marrow.
ALL is the most common type of cancer in children, according to the Leukaemia & Lymphoma Society. This study illuminates genetic understanding of this disease in children with the worst outcomes, including relapse and/or death.
The study team explored the DNA of leukaemia cells to look for common changes. “We found a barely noticeable area of DNA, known as 22q11.22, to be missing in about 30–40% of paediatric B-cell ALL patients,” says Joshua Schiffman, MD, co-senior author on the study.
Schiffman is a paediatric cancer physician-scientist at Huntsman Cancer Institute (HCI) and professor of paediatrics at the University of Utah (U of U).
“We began to wonder if something so small was missing so often, could this missing piece of DNA impact survival?” That’s when the study team turned their attention to a much better-known gene in childhood leukaemia called IKZF1.
“IKZF1 changes have puzzled doctors for some time,” explains Luke Maese, DO, a paediatric oncologist at HCI and associate professor of paediatrics at the U of U who cares for children with leukaemia at Intermountain Primary Children’s Hospital.
“We have known for over a decade that IKZF1 changes predict a very poor outcome in some, but not all, patients.” The study team began to investigate if this missing part of 22q11.22 could work together with IKZF1 changes to more reliably predict outcomes.
“Sure enough, we found that patients with both the 22q11.22 deletion and the IKZF1 changes—collectively known as a ‘double deletion’—had some of the worst outcomes in childhood leukaemia,” says Schiffman.
The team found that patients who already had an IKZF1 alteration had almost twice the risk of relapse if they also had a deletion in the 22q11.22 region.
The research team utilised sophisticated genomic analysis techniques to evaluate both inherited and environmental changes in the tumours of children with B-cell ALL. They evaluated genomic information of childhood cancer patients across multiple states and countries.
The study included cohorts of childhood leukaemia patients who had Down syndrome. Children with Down syndrome carry a higher risk of leukaemia.
David Spencer Mangum, MD, co-lead author and now an assistant professor of paediatric haematology/oncology at Nemours Children’s Health, remembers when he started working on this study more than 10 years ago as a medical student visiting Schiffman’s lab at HCI.
“Throughout all of my years in training, we never stopped trying to understand how this 22q11.22 deletion could impact children with leukaemia.
We gathered data from many different clinical trials to make sure this finding was real and reproducible,” explains Mangum.
“Our findings are significant because we found that the likelihood of relapse and death was consistent across multiple different cohorts of children with ALL, including children with Down syndrome.”
The research team hopes this finding can yield new insights into treatments for childhood leukaemia.
For example, the frequency of the 22q11.22 focal deletion indicates it may be important for leukaemia development, and the combined association with worse outcomes means it could be a useful clinical prognostic marker in the future.
“Kids with double deleted leukaemia may need more treatment—or bone marrow transplants right away—whereas kids without double deletion may require less toxic chemotherapy to still achieve excellent outcomes. All of this needs to be further explored,” says Schiffman.
The study was funded by the National Institutes of Health/National Cancer Institute including CA042014 and CA021765; the Pediatric Cancer Research Program funded by Intermountain Healthcare, Primary Children’s Hospital Foundation, and Department of Pediatrics at University of Utah; the Leukemia & Lymphoma Society Translational Research Program; the American Lebanese Syrian Associated Charities; and Huntsman Cancer Foundation.
The study benefited from insights of Professor Sir Mel Greaves, an internationally renowned expert on childhood leukaemia.
The authors acknowledge the critical role of each individual and institution involved in the collaboration, including other study co-first authors Clinton Mason, PhD, of University of Utah Health; and Julia Meyer, PhD, of the University of California, San Francisco; and co-senior author Karen Rabin, MD, PhD, of Baylor University.
Source: Huntsman Cancer Institute
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.